Search

Displaying results 6871 - 6880 of 9317 in total
  1. Drug

    Ravagalimab

    go.drugbank.com/drugs/DB16676
    Investigational

    Ravagalimab is under investigation in clinical trial NCT03695185 (A Study to Investigate How Well Ravagalimab (ABBV-323) Works and How Safe It Is in Participants With Moderate to Severe Ulcerative Colitis

  2. Drug

    RD06-04

    go.drugbank.com/drugs/DB24647
    Investigational

    RD06-04 is under investigation in clinical trial NCT06986018 (Clinical Study on the Targeted CD19 Universal CAR-T Cell Injection (RD06-04) for the Treatment of IIM and AAV).

  3. Drug

    EVT 302

    go.drugbank.com/drugs/DB06057
    Investigational

    It is in the development for smoking cessation, and potential for disease modification in Alzheimer's disease.

  4. Drug

    ISIS 113715

    go.drugbank.com/drugs/DB05506
    Investigational

    ISIS 113715 is our second-generation antisense inhibitor of protein tyrosine phosphatase 1b, or PTP‑1b, for the treatment of type 2 diabetes.

  5. Drug

    LX6171

    go.drugbank.com/drugs/DB05180
    Investigational

    LX6171 is an oral drug candidate that was generated by Lexicon medicinal chemists and is being developed to treat disorders characterized by cognitive impairment, such as Alzheimer's disease, schizophrenia

  6. Drug

    Tasquinimod

    go.drugbank.com/drugs/DB05861
    Investigational

    The quinoline-3-carboxamide anti-angiogenic agent, tasquinimod, enhances the anti-prostate cancer efficacy of androgen ablation and taxotere without effecting serum PSA directly in human xenografts

  7. Drug

    Reloxiliase

    go.drugbank.com/drugs/DB17653
    Experimental

    Reloxiliase is a first-in-class, oral crystalline formulation of the oxalate-specific, microbial enzyme oxalate decarboxylase. It is being investigated for the treatment of hyperoxaluria.[A258823]

  8. Drug

    Timbetasin

    go.drugbank.com/drugs/DB19119
    Investigational

    Timbetasin is under investigation in clinical trial NCT05555589 (Assessment of the Safety and Efficacy of 0.1% RGN-259 Ophthalmic Solution for the Treatment of NK: SEER-2).

    Synonyms: 3,11,25,31,38-pentakis(de-n6-acetyl)-1,22,30,33-tetrakis(de-o3-phosphono)thymosin .beta.4(human), Thymosin .beta.(4), 3,11,25,31,38-pentakis(de-n6-acetyl)-1,22,30,33-tetrakis(de-o3-phosphono)-
  9. Drug

    AG0301-COVID19

    go.drugbank.com/drugs/DB15856
    Investigational

    The candidate is a plasmid DNA vaccine developed using an intradermal gene transfer method targeting the SARS-CoV-2 spike protein. … The gene transfer method increases the efficiency of gene expression and antibody production capability, garnering a more efficient DNA vaccine product.

  10. Drug

    Mivebresib

    go.drugbank.com/drugs/DB21300
    Investigational

    The usage of the INN stem '-bresib' in the name indicates that Mivebresib is a inhibitor of the bromodomain and extra-terminal motif (BET) family of bromodomain (BRD) protein, antineoplastic.